Trevi Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Trevi Therapeutics

11/05/2023 22:55

* Trevi Therapeutics Inc  TRVI.OQ  reported a quarterly
adjusted
loss of 6 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 7 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Trevi Therapeutics Inc's reported EPS for the quarter was
a loss
of 6 cents​.
    * The mean earnings estimate of analysts had risen by
about 29% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Trevi Therapeutics Inc shares had risen by 56.8% this
quarter and gained 50.3% so far this year.
    * The company reported a quarterly loss of $6.4 million.
    * Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $7.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:55 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.07          -0.06          Beat
 Dec. 31 2022      -0.10          -0.06          Beat
 Sep. 30 2022      -0.13          -0.12          Beat
 Jun. 30 2022      -0.18          -0.14          Beat